Compare CLDX & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLDX | TMDX |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 1995 | 2019 |
| Metric | CLDX | TMDX |
|---|---|---|
| Price | $38.90 | $86.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | $46.60 | ★ $148.22 |
| AVG Volume (30 Days) | ★ 694.0K | 589.9K |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 0.61 |
| Revenue | $12,743,000.00 | ★ $605,494,000.00 |
| Revenue This Year | $111.39 | $24.25 |
| Revenue Next Year | $235.85 | $18.75 |
| P/E Ratio | ★ N/A | $144.70 |
| Revenue Growth | ★ 87.78 | 37.13 |
| 52 Week Low | $22.10 | $60.11 |
| 52 Week High | $45.14 | $156.00 |
| Indicator | CLDX | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 50.89 |
| Support Level | $28.51 | $66.64 |
| Resistance Level | $40.30 | $95.18 |
| Average True Range (ATR) | 1.37 | 3.84 |
| MACD | -0.36 | -0.88 |
| Stochastic Oscillator | 9.94 | 39.52 |
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.